PTC Therapeutics, Inc. (PTCT) FY2026 YTD Q3 P&L / Income Statement
Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)
Revenue by Product and Service (3 categories)
Swipe to see the full flow
Chart details
PTC Therapeutics, Inc. (PTCT) FY2026 YTD Q3 P&L / Income Statement
Income statement for 2026-01-01 through 2026-09-30. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 990,877,000 US dollars
- Total operating expenses
- 771,827,000 US dollars
- Income from operations
- 219,050,000 US dollars
- Other income (expense), net (calculated)
- negative 165,055,000 US dollars
- (Loss) income before income tax (expense) benefit
- 53,995,000 US dollars
- Income tax (expense) benefit
- 25,001,000 US dollars
- Net (loss) income attributable to common stockholders
- 28,994,000 US dollars
- Net product revenue
- 740,286,000 US dollars
- Collaboration and license revenue
- 50,967,000 US dollars
- Royalty revenue
- 199,624,000 US dollars
- Total operating expenses
- 771,827,000 US dollars
Chart connections
- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!
